Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.


Characterization of New Drug’s Safety Profile Before Marketing

Friedman MA et al. JAMA 1999; 281(18):1728–1734
  • Most drugs approved by FDA with average of 1500 patient exposures
  • Some drugs have rare toxicity profiles (bromfenac hepatotoxicity 1 in 20,000 patients)
  • For drugs with rare toxicity, more than 100,000 patients must be exposed to generate a signal i.e. after drug is marketed


Back to Learning Module

Page Last Updated: 10/12/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English